Ajanta Pharma announced its Q2 September 2020 results yesterday (3 November). On a consolidated basis, the company’s net profit increased 46.29% to Rs 170.22 crore on a 11.38% rise in revenue from operations to Rs 715.91 crore in Q2 September 2020 over Q2 September 2019.
Profit before tax (PBT) jumped 54.27% to Rs 249.24 crore in Q2 September 2020 over Q2 September 2019. Current tax expense surged 105.55% to Rs 82.59 crore in Q2 September 2020 as against Rs 40.18 crore in Q2 September 2019.
Ajanta Pharma Buyback: Ajanta Pharma Also Announced buyback of Equity shares 7.35 lakhs shares (representing 0.84 per cent of the total paid-up share capital) at ₹1,850 a share.
To know Ajanta Pharma Buyback Detail: Click Here
Ajanta Pharma Q2 net profit increased 46.29% to Rs 170.22 crore on a 11.38% rise in revenue from operations to Rs 715.91 crore; firm announces dividend at Rs 18 per share.
Ajanta Pharma Dividend Details
|Ajanta Pharma Dividend Type||INTERIM|
|Ajanta Pharma Dividend Price||Rs. 9.50/-|
|Ajanta Pharma Dividend Announcement Date||03.11.2020|
|Ajanta Pharma Dividend Ex-Dividend Date||12.11.2020|
|Ajanta Pharma Dividend Record Date||13.11.2020|
|Ajanta Pharma Dividend (%)||475%|
|Ajanta Pharma Dividend Payment Date||20.11.2020|
|Ajanta Pharma Quarterly Result||September Q2|
|Face Value (FV):||2|
|Board Meeting held on||03.11.2020|
Ajanta Pharma Dividend Percentage & Record Date
|Announcement||Record Date||Dividend Type||Dividend %||Dividend Price|
About Ajanta Pharma Company:
Ajanta Pharma Limited is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, Asia, Middle East, and CIS. It was established in 1973
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Ajanta Pharma produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customized to each market. We clearly understand our customer’s needs and use cutting edge technology to present innovative solutions. Our business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.